Save this content for laterSave this content on your device for later, even while offline Sign in with FacebookSign in with your Facebook account Close

FDA approves 1st nonopioid drug to ease withdrawal symptoms

By: LINDA A. JOHNSON, Associated Press
May 16, 2018 Updated: May 16, 2018 at 6:06 pm
0
photo - This undated photo provided by US WorldMeds shows Lucemyra. Federal regulators have approved the first nonopioid treatment to ease withdrawal symptoms from quitting opioids. (US WorldMeds via AP)
This undated photo provided by US WorldMeds shows Lucemyra. Federal regulators have approved the first nonopioid treatment to ease withdrawal symptoms from quitting opioids. (US WorldMeds via AP) 

TRENTON, N.J. (AP) — Federal regulators on Wednesday approved the first nonopioid treatment to ease withdrawal from quitting addictive opioids.

The U.S. Food and Drug Administration expedited approval of Lucemyra to help combat the U.S. opioid epidemic. Two-thirds of drug overdose deaths in 2016 involved opioids, mostly fentanyl, heroin and prescription painkillers.

The pill was approved to treat adults for up to two weeks for common withdrawal symptoms like vomiting, diarrhea, muscle pain and agitation. It is not an addiction medicine but can be part of a longer-term treatment plan, according to the FDA.

People going through detox are usually given a safer opioid medicine like methadone, which eases the cravings without an intense high.

"The fear of experiencing withdrawal symptoms often prevents those suffering from opioid addiction from seeking help," FDA Commissioner Dr. Scott Gottlieb said in a statement.

In two studies of 866 adults, those given Lucemyra reported less severe withdrawal symptoms when they abruptly stopped taking opioids, compared to those who were given dummy pills.

Side effects included low blood pressure, dizziness, sleepiness, slow heart rate and, in a few people, fainting.

The FDA is requiring drugmaker US WorldMeds of Louisville, Kentucky, to conduct more studies in teens and newborns of opioid-addicted mothers and for possible longer-term use in people tapering off opioids.

Privately held US WorldMeds said it had not yet set a price for Lucemyra.

___

Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma

Register to the Colorado Springs Gazette
Incognito Mode Your browser is in Incognito mode

You vanished!

We welcome you to read all of our stories by signing into your account. If you don't have a subscription, please subscribe today for daily award winning journalism.

Register to the Colorado Springs Gazette
Subscribe to the Colorado Springs Gazette

It appears that you value local journalism. Thank you.

Subscribe today for unlimited digital access with 50% fewer ads for a faster browsing experience.

Already a Subscriber? LOGIN HERE

Wake up with today's top stories in your inbox

Wake up with today's top stories in your inbox

or
Already a print subscriber?
Already a digital subscriber?
 
This is your last FREE article for the month
This is your last FREE article for the month

Subscribe now and enjoy Unlimited Digital Access to Gazette.com

Only 99 cents for Unlimited Digital Access for 1 month
Then $2.31/week, billed monthly, cancel anytime
Already a print subscriber?
Already a digital subscriber?

 
You have reached your article limit for the month
You have reached your article limit for the month

We hope that you've enjoyed your complimentary access to Gazette.com

Only 99 cents for Unlimited Digital Access for 1 month
Then $2.31/week, billed monthly, cancel anytime
Already a print subscriber?
Already a digital subscriber?
 

Exclusive Subscriber Content

You read The Gazette because you care about your community and the local stories you can't find anywhere else.

Only 99 cents for Unlimited Digital Access for 1 month
Then $2.31/week, billed monthly, cancel anytime
Already a print subscriber? Get Access | Already a digital subscriber? Log In
 
articles remaining
×
Thank you for your interest in local journalism.
Gain unlimited access, 50% fewer ads and a faster browsing experience.